

Special Issue

Management and Treatment of Cardiometabolic Disorders Across the Lifespan

Message from the Guest Editors

Cardiometabolic disorders encompass a spectrum of interrelated conditions including metabolic syndrome, obesity, type 2 diabetes mellitus, hypertension, dyslipidemia, chronic kidney disease (CKD), and atherosclerotic cardiovascular disease (ASCVD). These disorders share overlapping pathophysiological pathways—primarily driven by insulin resistance, ectopic adiposity, and chronic inflammation—that link cardiovascular, renal, and metabolic health. The interconnectedness of these systems means that dysfunction in one often accelerates pathology in the others, necessitating integrated management strategies. Pharmacological and surgical management are indicated when lifestyle interventions are insufficient or when comorbidities are present. Pharmacotherapies include sodium–glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, mineralocorticoid receptor antagonists, and combination therapies, which target multiple pathophysiological pathways and are particularly effective in patients with diabetes, CKD, and ASCVD. Both clinical and preclinical papers are welcome.

Guest Editors

Dr. Pasquale Mone

Department of Medicine and Health Sciences “Vincenzo Tiberio”,
University of Molise, Campobasso, Italy

Dr. Maria Luisa D’Onghia

Plastic Surgery, University of Bari “Aldo Moro”, Bari, Italy

Dr. Luigi Simone Aversa

Department of Medical Science, Division of Endocrinology, Diabetes
and Metabolism, University of Turin, Turin, Italy

Deadline for manuscript submissions

5 October 2026



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/276311

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)